brodalumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
human origin 5179 1174395-19-7

Description:

MoleculeDescription

Synonyms:

  • kyntheum
  • brodalumab
  • AMG 827
  • AMG-827
Brodalumab is a human monoclonal IgG2 antibody that selectively binds to human IL-17RA and inhibits its interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer and IL-25. IL-17RA is a protein expressed on the cell surface and is a required component of receptor complexes utilized by multiple IL-17 family cytokines. Blocking IL­17RA inhibits IL-17 cytokine-induced responses including the release of pro-inflammatory cytokines and chemokines.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
15 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
July 17, 2017 EMA LEO Pharma A/S
Feb. 15, 2017 FDA VALEANT LUXEMBOURG
July 4, 2016 PMDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Collagen-vascular disease 60.84 34.18 8 1325 92 90627022
Palmoplantar pustulosis 60.14 34.18 10 1323 604 90626510
Patient dissatisfaction with treatment 50.82 34.18 8 1325 342 90626772
Parakeratosis 50.82 34.18 8 1325 342 90626772
Cutaneous T-cell lymphoma 38.58 34.18 8 1325 1612 90625502
Psoriasis 38.44 34.18 25 1308 147729 90479385
Seborrhoeic dermatitis 38.10 34.18 8 1325 1712 90625402
Psoriatic arthropathy 37.13 34.18 29 1304 228306 90398808
Drug ineffective 36.49 34.18 69 1264 1384229 89242885

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriatic arthropathy 152.77 34.45 50 1480 24917 42594888
Psoriasis 75.10 34.45 36 1494 48568 42571237
Therapy interrupted 58.64 34.45 24 1506 22226 42597579
Arthralgia 57.65 34.45 52 1478 205186 42414619
Dermatitis infected 54.63 34.45 9 1521 205 42619600
Tinea pedis 44.20 34.45 11 1519 2037 42617768
Peripheral venous disease 39.91 34.45 11 1519 3025 42616780

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 107.31 28.93 58 2787 139935 110446519
Psoriatic arthropathy 93.95 28.93 60 2785 196701 110389753
Patient dissatisfaction with treatment 73.36 28.93 12 2833 369 110586085
Therapy interrupted 59.76 28.93 28 2817 49794 110536660
Collagen-vascular disease 57.37 28.93 8 2837 80 110586374
Parakeratosis 55.99 28.93 10 2835 521 110585933
Drug ineffective 53.66 28.93 119 2726 1520421 109066033
Dermatitis infected 49.61 28.93 9 2836 512 110585942
Tinea pedis 49.17 28.93 12 2833 2863 110583591
Disease recurrence 48.76 28.93 26 2819 60758 110525696
Palmoplantar pustulosis 43.88 28.93 9 2836 977 110585477
Arthralgia 41.86 28.93 73 2772 779559 109806895
Suicidal ideation 40.69 28.93 27 2818 93910 110492544
Cutaneous lymphoma 34.24 28.93 6 2839 280 110586174
Psoriasis area severity index increased 34.05 28.93 6 2839 289 110586165
Dermatitis exfoliative generalised 33.30 28.93 12 2833 10960 110575494
Pustule 32.54 28.93 9 2836 3495 110582959
Hepatocellular carcinoma 30.72 28.93 11 2834 9869 110576585
Seborrhoeic dermatitis 30.03 28.93 8 2837 2699 110583755

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AC12 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Interleukin inhibitors
FDA CS M0001357 Antibodies, Monoclonal
MeSH PA D003879 Dermatologic Agents
FDA EPC N0000193276 Interleukin-17 Receptor A Antagonist
FDA MoA N0000193279 Interleukin 17 Receptor A Antagonists
CHEBI has role CHEBI:35842 antirheumatic drug
CHEBI has role CHEBI:50748 antipsoriatic
CHEBI has role CHEBI:65023 anti-asthmatic agent
CHEBI has role CHEBI:67079 anti-inflammatory agent

Related Drugs by ATC class:

L04AC Interleukin inhibitors 18 drugs
anakinrabasiliximabbimekizumabcanakinumabdaclizumabguselkumabixekizumabmirikizumabrilonaceptrisankizumabsarilumabsatralizumab show all 18 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Ankylosing spondylitis indication 9631008 DOID:7147
Palmoplantar pustulosis indication 27520001 DOID:4398
Psoriatic arthritis indication 156370009 DOID:9008
Plaque psoriasis indication 200965009
Pustular psoriasis indication 200973000
Erythrodermic psoriasis indication 200977004
Non-radiographic axial spondyloarthritis indication 713777005
Crohn's disease contraindication 34000006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Interleukin-17 receptor Membrane receptor ANTIBODY BINDING Kd 9.20 IUPHAR SCIENTIFIC LITERATURE

External reference:

IDSource
6ZA31Y954Z UNII
4036541 VANDF
C3491331 UMLSCUI
CHEBI:750076 CHEBI
CHEMBL1742996 ChEMBL_ID
D10061 KEGG_DRUG
DB11776 DRUGBANK_ID
9475 INN_ID
C571216 MESH_SUPPLEMENTAL_RECORD_UI
7540 IUPHAR_LIGAND_ID
726519005 SNOMEDCT_US
763604008 SNOMEDCT_US
32390 MMSL
d08529 MMSL
017103 NDDF
1872251 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Siliq HUMAN PRESCRIPTION DRUG LABEL 1 0187-0004 INJECTION 210 mg SUBCUTANEOUS BLA 26 sections